Every medicine that reaches a patient has to prove one thing above all: that it can be made the same way, to the same quality, every single time. That proof is CMC – Chemistry, Manufacturing and Controls. It is the body of technical and regulatory work that demonstrates a drug’s identity, strength, purity and consistency, from the first laboratory batch through to commercial supply.
This article explains what CMC means in pharmaceutical development, how it applies to clinical trials, process development and biotech, and why it pays to plan it early.
What Does CMC Mean in Pharmaceutical Development?
CMC stands for Chemistry, Manufacturing and Controls. In medicine and pharmaceutical development, it’s the documented evidence that a drug product is well characterised, reliably manufactured and properly controlled across its lifecycle. It brings together four connected areas:
- Drug substance (API): The structure, characterisation and manufacturing route of the active ingredient.
- Drug product: The finished formulation, its stability, packaging and container-closure system.
- Analytical methods: The clinical phase-appropriate validated tests that confirm identity, purity and potency.
- Manufacturing controls: The batch records, in-process checks, scale-up steps and quality systems that keep every batch within specification.
Put simply, CMC is how you prove a drug is made by a repeatable, scalable process and is safe to give to patients. Regulators and ethics committees require this evidence before a product can be tested in humans, and agencies such as the TGA, FDA and EMEA assess it in full before a product can be sold; so CMC sits underneath every submission a developer makes.
What is CMC in Clinical Trials?
Once a candidate is ready for humans, CMC governs the material that goes into the study. The investigational product must be manufactured to Good Manufacturing Practice (GMP), tested against a specification and formally released before it can be dosed. That CMC information forms a core part of the clinical trial submission. The Investigational New Drug (IND) application in the United States, or the quality data supporting a trial under Australia’s CTN or CTA schemes, is alongside the safety data that regulators and ethics committees expect.
The CMC package is not static. As a program moves from first-in-human (Phase 1) through Phase II and III, the demands grow; larger batches, tighter impurity profiles, and longer stability data to support later-stage and commercial use. Getting this right keeps supply flowing to clinical sites without holds or deviations. PharmSky’s clinical trial manufacturing is built to produce and release this material to GMP for both early-phase and later-phase studies.
What is CMC Process Development?
CMC process development is the work of designing and refining how a drug is actually made. The goal is a manufacturing process that produces the same quality product, batch after batch, at every scale from the laboratory to full production.
This increasingly applies Quality by Design (QbD) principles: identifying the critical quality attributes of the product, then using structured studies such as Design of Experiments to understand which materials and process parameters drive them. Once a well-defined design space is established, the process can be scaled up and transferred to a manufacturing site with confidence that it will behave predictably.
Strong process development early on prevents costly rework later. For example, a change to the process later in development can trigger new stability studies or fresh regulatory questions. PharmSky’s formulation development work supports this stage, turning a candidate into a stable, manufacturable product.
What is CMC in Biotech?
Biotech brings CMC challenges that small-molecule drugs rarely face. Biologics, proteins, antibodies, and cell and gene therapies are made in living systems, so they are harder to characterise and more sensitive to small changes in the process. A minor shift in cell line, media or handling can alter the product, which means analytical characterisation and tight process control carry even more weight than usual.
For emerging biotech companies, this has a practical consequence; CMC cannot be an afterthought. The process is often inseparable from the product, and the data you generate early shapes what you can claim later. Building a sound CMC and analytical foundation from the outset helps a biotech move through the clinic and toward approval without having to unpick decisions made under time pressure.
Why CMC Matters from Day One
CMC is often underestimated in early development, yet gaps in it are a well-known cause of regulatory delay, clinical holds and expensive rework. The pattern is consistent; teams that treat CMC as late-stage paperwork tend to hit avoidable problems at exactly the wrong moment.
Starting early changes the trajectory. Planning CMC during preclinical work, aligning laboratory methods with future scale-up and validation needs, and running a risk-based quality system all reduce the chance of a setback before a key milestone. Done well, CMC is not a compliance burden, it’s the foundation that lets a program move quickly and scale cleanly from first dose to market.
Partnering with a CDMO for CMC
Few early-stage developers have every CMC capability in-house, which is why many partner with a contract development and manufacturing organisation (CDMO). An integrated CDMO brings formulation, analytical testing and GMP manufacturing together, so the data and documentation generated at each step carry cleanly into the next, and then ultimately, into the regulatory dossier.
That integration is the point. When formulation, method development and clinical manufacturing sit under one roof, there are fewer handovers, less duplicated work and a tighter, more defensible CMC story. PharmSky’s analytical services sit alongside its formulation and clinical manufacturing capabilities to support developers across the program.
Ready to strengthen your CMC?
Looking for CMC support in Australia? PharmSky is a local CDMO offering integrated formulation development, analytical testing and GMP clinical trial manufacturing. Get in touch to discuss your program.
Frequently Asked Questions About CMC
What does CMC stand for?
CMC stands for Chemistry, Manufacturing and Controls; the technical and regulatory evidence that a drug is made consistently to specification and safely.
When should CMC work start?
As early as practical. Beginning CMC and analytical planning in preclinical development helps avoid delays, rework and stability gaps at later, higher stakes milestones.
